McNeil to launch Children's Motrin oral suspension in the fall following June 16 approval.
This article was originally published in The Tan Sheet
Executive Summary
McNEIL LAUNCHING CHILDREN'S MOTRIN IN THE FALL following FDA approval of the Rx-to-OTC switch on June 16, the Johnson & Johnson subsidiary announced June 19. The first OTC liquid suspension with ibuprofen for children, Children's Motrin ibuprofen oral suspension (100 mg per 5 ml) will be indicated for two- to 11-year-olds for the reduction of fever and relief of minor aches and pain due to colds, flu, sore throat, headaches and toothaches for up to eight hours. The recommended dose is 7.5 mg/kg up to four times a day, with a maximum daily dose of 30 mg/kg.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning